A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062

Last updated date
Study Location
Mater Hospital
South Brisbane, Queensland, 4101, Australia
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.

2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.

4. Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of enrollment (signing of the ICD).

5. Subjects must have received the primary vaccination (RSV vaccine or placebo) at Visit 1 and have signed and dated the ICD for participating in the revaccination stage (applies to Primary Study Cohort - Stage 2 subjects).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.


2. Participation in other studies involving investigational product within 28 days prior
to study entry and/or during study participation.


3. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).


4. Previous vaccination with any licensed or investigational RSV vaccine before
enrollment into the study, or planned receipt throughout the study of nonstudy RSV
vaccine.


5. Vaccination with any influenza vaccine within 6 months (182 days) before
investigational product administration (applies to Primary Study Cohort - Stages 1 and
2).


6. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the investigational product(s),
including natural rubber latex. In addition, a history of severe allergic reaction
(eg, anaphylaxis) to any substance, including documented allergy to egg proteins (egg
or egg products) or chicken proteins.


7. Subjects with known or suspected immunodeficiency, as determined by history and/or
laboratory/physical examination.


8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
planned receipt throughout the study. If systemic corticosteroids have been
administered short term (<14 days) for treatment of an acute illness, subjects should
not be enrolled into the study until corticosteroid therapy has been discontinued for
at least 28 days before investigational product administration.Inhaled/nebulized,
intra-articular, intrabursal, or topical (epidural, skin or eyes) corticosteroids are
permitted.


9. Subject with a history of autoimmune disease or an active autoimmune disease requiring
therapeutic intervention including but not limited to: systemic or cutaneous lupus
erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré
syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura,
autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal
arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).


10. Receipt of blood/plasma products or immunoglobulin, from 60 days before
investigational product administration or planned receipt throughout the study.


11. Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.


12. Female subjects of childbearing potential or who are pregnant or breastfeeding;
fertile male subjects who are unwilling to use a highly effective method of
contraception for at least 28 days after the last dose of investigational product.


13. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.


14. Planned donation of blood volumes of approximately 470 mL within 12 weeks after
Vaccination 1 (applies to subjects having additional blood drawn for cellular assays).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Mobile, Alabama
  2. Houston, Texas
  3. Houston, Texas
  4. San Antonio, Texas
  5. Quebec,
  6. Helsinki,
  7. Pori,
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Birmingham, Alabama
  12. Birmingham, Alabama
  13. Birmingham, Alabama
  14. Birmingham, Alabama
  15. Birmingham, Alabama
  16. Birmingham, Alabama
  17. Cullman, Alabama
  18. Cullman, Alabama
  19. Cullman, Alabama
  20. Phoenix, Arizona
  21. Phoenix, Arizona
  22. Phoenix, Arizona
  23. Tucson, Arizona
  24. Tucson, Arizona
  25. Chowchilla, California
  26. Huntington Park, California
  27. Huntington Park, California
  28. Huntington Park, California
  29. Lancaster, California
  30. Lancaster, California
  31. Long Beach, California
  32. Long Beach, California
  33. Long Beach, California
  34. Los Angeles, California
  35. Los Angeles, California
  36. Madera, California
  37. Madera, California
  38. Madera, California
  39. Madera, California
  40. Santa Monica, California
  41. Santa Monica, California
  42. Santa Monica, California
  43. Stanford, California
  44. Thousand Oaks, California
  45. Ventura, California
  46. Aurora, Colorado
  47. Aurora, Colorado
  48. Aurora, Colorado
  49. Aurora, Colorado
  50. Aurora, Colorado
  51. Aurora, Colorado
  52. Aurora, Colorado
  53. Aurora, Colorado
  54. Delta, Colorado
  55. Fruita, Colorado
  56. Grand Junction, Colorado
  57. Grand Junction, Colorado
  58. Grand Junction, Colorado
  59. Grand Junction, Colorado
  60. Grand Junction, Colorado
  61. Montrose, Colorado
  62. Washington, District of Columbia
  63. Washington, District of Columbia
  64. Washington, District of Columbia
  65. Loxahatchee Groves, Florida
  66. Miami, Florida
  67. North Miami Beach, Florida
  68. North Miami Beach, Florida
  69. Panama City, Florida
  70. Panama City, Florida
  71. Panama City, Florida
  72. Panama City, Florida
  73. Pembroke Pines, Florida
  74. Pembroke Pines, Florida
  75. Atlanta, Georgia
  76. Atlanta, Georgia
  77. Atlanta, Georgia
  78. Atlanta, Georgia
  79. Columbus, Georgia
  80. Columbus, Georgia
  81. Blackfoot, Idaho
  82. Blackfoot, Idaho
  83. Blackfoot, Idaho
  84. Idaho Falls, Idaho
  85. Idaho Falls, Idaho
  86. Nampa, Idaho
  87. Nampa, Idaho
  88. Nampa, Idaho
  89. Pocatello, Idaho
  90. Pocatello, Idaho
  91. Fort Wayne, Indiana
  92. Fort Wayne, Indiana
  93. Ames, Iowa
  94. Ames, Iowa
  95. Ames, Iowa
  96. Ames, Iowa
  97. Ankeny, Iowa
  98. West Des Moines, Iowa
  99. West Des Moines, Iowa
  100. El Dorado, Kansas
  101. Kansas City, Kansas
  102. Newton, Kansas
  103. Wichita, Kansas
  104. Wichita, Kansas
  105. Owensboro, Kentucky
  106. Owensboro, Kentucky
  107. Alexandria, Louisiana
  108. Alexandria, Louisiana
  109. Covington, Louisiana
  110. Gretna, Louisiana
  111. Lafayette, Louisiana
  112. Metairie, Louisiana
  113. New Orleans, Louisiana
  114. New Orleans, Louisiana
  115. New Orleans, Louisiana
  116. New Orleans, Louisiana
  117. New Orleans, Louisiana
  118. New Orleans, Louisiana
  119. New Orleans, Louisiana
  120. New Orleans, Louisiana
  121. Slidell, Louisiana
  122. Boston, Massachusetts
  123. Boston, Massachusetts
  124. Blaine, Minnesota
  125. Coon Rapids, Minnesota
  126. Coon Rapids, Minnesota
  127. Coon Rapids, Minnesota
  128. Fridley, Minnesota
  129. Maple Grove, Minnesota
  130. Minneapolis, Minnesota
  131. Minneapolis, Minnesota
  132. Minneapolis, Minnesota
  133. Bay Saint Louis, Mississippi
  134. Gulfport, Mississippi
  135. Saint Louis, Missouri
  136. Butte, Montana
  137. Great Falls, Montana
  138. Helena, Montana
  139. Kalispell, Montana
  140. Missoula, Montana
  141. Grand Island, Nebraska
  142. Hastings, Nebraska
  143. Lincoln, Nebraska
  144. Lincoln, Nebraska
  145. Lincoln, Nebraska
  146. Lincoln, Nebraska
  147. Norfolk, Nebraska
  148. Las Vegas, Nevada
  149. Las Vegas, Nevada
  150. Las Vegas, Nevada
  151. Albuquerque, New Mexico
  152. Albuquerque, New Mexico
  153. East Setauket, New York
  154. East Setauket, New York
  155. East Setauket, New York
  156. Endwell, New York
  157. Johnson City, New York
  158. Mineola, New York
  159. Mineola, New York
  160. Mineola, New York
  161. Mineola, New York
  162. New Hyde Park, New York
  163. Stony Brook, New York
  164. Durham, North Carolina
  165. Durham, North Carolina
  166. Durham, North Carolina
  167. Durham, North Carolina
  168. Pinehurst, North Carolina
  169. Pinehurst, North Carolina
  170. Seven Lakes, North Carolina
  171. Southern Pines, North Carolina
  172. Southern Pines, North Carolina
  173. Dayton, Ohio
  174. Englewood, Ohio
  175. Yukon, Oklahoma
  176. Erie, Pennsylvania
  177. Erie, Pennsylvania
  178. Erie, Pennsylvania
  179. Erie, Pennsylvania
  180. West Reading, Pennsylvania
  181. West Reading, Pennsylvania
  182. West Reading, Pennsylvania
  183. Charleston, South Carolina
  184. Charleston, South Carolina
  185. Greenville, South Carolina
  186. Greenville, South Carolina
  187. Greenville, South Carolina
  188. Summerville, South Carolina
  189. Summerville, South Carolina
  190. Clarksville, Tennessee
  191. Knoxville, Tennessee
  192. Arlington, Texas
  193. Austin, Texas
  194. Beaumont, Texas
  195. Beaumont, Texas
  196. Beaumont, Texas
  197. Beaumont, Texas
  198. Burleson, Texas
  199. Dallas, Texas
  200. Dickinson, Texas
  201. Fort Worth, Texas
  202. Fort Worth, Texas
  203. Galveston, Texas
  204. Georgetown, Texas
  205. Georgetown, Texas
  206. Georgetown, Texas
  207. Georgetown, Texas
  208. Grapevine, Texas
  209. Houston, Texas
  210. Houston, Texas
  211. Houston, Texas
  212. Houston, Texas
  213. Houston, Texas
  214. Houston, Texas
  215. Houston, Texas
  216. Houston, Texas
  217. Lampasas, Texas
  218. Lampasas, Texas
  219. League City, Texas
  220. Longview, Texas
  221. Longview, Texas
  222. Longview, Texas
  223. Longview, Texas
  224. McAllen, Texas
  225. Plano, Texas
  226. San Antonio, Texas
  227. Tomball, Texas
  228. Weatherford, Texas
  229. Murray, Utah
  230. Salt Lake City, Utah
  231. Salt Lake City, Utah
  232. Salt Lake City, Utah
  233. Salt Lake City, Utah
  234. Salt Lake City, Utah
  235. Salt Lake City, Utah
  236. Salt Lake City, Utah
  237. Salt Lake City, Utah
  238. Norfolk, Virginia
  239. Norfolk, Virginia
  240. Richmond, Virginia
  241. Richmond, Virginia
  242. Richmond, Virginia
  243. Richmond, Virginia
  244. Richmond, Virginia
  245. Richmond, Virginia
  246. Richmond, Virginia
  247. Seattle, Washington
  248. Seattle, Washington
  249. Seattle, Washington
  250. Seattle, Washington
  251. Seattle, Washington
  252. Seattle, Washington
  253. Seattle, Washington
  254. Shoreline, Washington
  255. Tacoma, Washington
  256. Tacoma, Washington
  257. Tacoma, Washington
  258. Tacoma, Washington
  259. Tacoma, Washington
  260. Huntington, West Virginia
  261. Huntington, West Virginia
  262. Huntington, West Virginia
  263. Huntington, West Virginia
  264. Geelong, Victoria
  265. Santiago, Región Metropolitana
  266. Santiago, Región Metropolitana
  267. Santiago, Región Metropolitana
  268. Kokkola,
  269. Oulu,
  270. Seinajoki,
  271. Tampere,
  272. Turku,
  273. Haarlem,
  274. Hoofddorp,
  275. Utrecht,
  276. Bloemfontein, FREE State
  277. Soshanguve, Gauteng
  278. Santiago de Compostela, A Coruna
  279. Antequera, Malaga
  280. Madrid,
  281. Madrid,
  282. Mostoles,
  283. Valencia,
  284. Kaohsiung,
  285. Taipei,
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Atlanta, Georgia
  2. Nampa, Idaho
  3. Salt Lake City, Utah
  4. San Miguel de Tucuman,
  5. Santiago, RM
  6. Soweto, Gauteng
  7. Birmingham, Alabama
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Cullman, Alabama
  11. Cullman, Alabama
  12. Cullman, Alabama
  13. Phoenix, Arizona
  14. Tucson, Arizona
  15. Tucson, Arizona
  16. Chowchilla, California
  17. Huntington Park, California
  18. Huntington Park, California
  19. Los Angeles, California
  20. Los Angeles, California
  21. Madera, California
  22. Madera, California
  23. Madera, California
  24. Madera, California
  25. Aurora, Colorado
  26. Aurora, Colorado
  27. Aurora, Colorado
  28. Aurora, Colorado
  29. Aurora, Colorado
  30. Aurora, Colorado
  31. Aurora, Colorado
  32. Atlanta, Georgia
  33. Blackfoot, Idaho
  34. Blackfoot, Idaho
  35. Blackfoot, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Idaho Falls, Idaho
  39. Idaho Falls, Idaho
  40. Idaho Falls, Idaho
  41. Idaho Falls, Idaho
  42. Nampa, Idaho
  43. Nampa, Idaho
  44. Nampa, Idaho
  45. Pocatello, Idaho
  46. Pocatello, Idaho
  47. Ankeny, Iowa
  48. West Des Moines, Iowa
  49. West Des Moines, Iowa
  50. El Dorado, Kansas
  51. Hutchinson, Kansas
  52. Alexandria, Louisiana
  53. Gretna, Louisiana
  54. Marrero, Louisiana
  55. Metairie, Louisiana
  56. Metairie, Louisiana
  57. New Orleans, Louisiana
  58. New Orleans, Louisiana
  59. Boston, Massachusetts
  60. Blaine, Minnesota
  61. Coon Rapids, Minnesota
  62. Coon Rapids, Minnesota
  63. Coon Rapids, Minnesota
  64. Coon Rapids, Minnesota
  65. Minneapolis, Minnesota
  66. Biloxi, Mississippi
  67. Gulfport, Mississippi
  68. Gulfport, Mississippi
  69. Gulfport, Mississippi
  70. Saint Louis, Missouri
  71. Saint Louis, Missouri
  72. Saint Louis, Missouri
  73. Missoula, Montana
  74. Missoula, Montana
  75. Lincoln, Nebraska
  76. Lincoln, Nebraska
  77. Lincoln, Nebraska
  78. Norfolk, Nebraska
  79. Henderson, Nevada
  80. Las Vegas, Nevada
  81. Albuquerque, New Mexico
  82. Albuquerque, New Mexico
  83. Albuquerque, New Mexico
  84. Binghamton, New York
  85. Endwell, New York
  86. Hempstead, New York
  87. Johnson City, New York
  88. Johnson City, New York
  89. Mineola, New York
  90. Mineola, New York
  91. Mineola, New York
  92. Mineola, New York
  93. Rochester, New York
  94. Rochester, New York
  95. Durham, North Carolina
  96. Durham, North Carolina
  97. Durham, North Carolina
  98. Durham, North Carolina
  99. Dayton, Ohio
  100. Dayton, Ohio
  101. Englewood, Ohio
  102. Kettering, Ohio
  103. Summerville, South Carolina
  104. Summerville, South Carolina
  105. Summerville, South Carolina
  106. Beaumont, Texas
  107. Beaumont, Texas
  108. Beaumont, Texas
  109. Beaumont, Texas
  110. Fort Worth, Texas
  111. Fort Worth, Texas
  112. Galveston, Texas
  113. Georgetown, Texas
  114. Georgetown, Texas
  115. Georgetown, Texas
  116. Georgetown, Texas
  117. Houston, Texas
  118. Houston, Texas
  119. Houston, Texas
  120. Houston, Texas
  121. Houston, Texas
  122. Houston, Texas
  123. Lampasas, Texas
  124. Lampasas, Texas
  125. Longview, Texas
  126. Longview, Texas
  127. Longview, Texas
  128. McAllen, Texas
  129. Pharr, Texas
  130. Plano, Texas
  131. Plano, Texas
  132. Round Rock, Texas
  133. Tomball, Texas
  134. Murray, Utah
  135. Salt Lake City, Utah
  136. Salt Lake City, Utah
  137. Salt Lake City, Utah
  138. Salt Lake City, Utah
  139. Salt Lake City, Utah
  140. Richmond, Virginia
  141. Richmond, Virginia
  142. Huntington, West Virginia
  143. Huntington, West Virginia
  144. Huntington, West Virginia
  145. Huntington, West Virginia
  146. San Miguel de Tucuman, Tucuman
  147. San Miguel de Tucuman, Tucuman
  148. Cordoba,
  149. Salta,
  150. Santiago, Region Metropolitana
  151. Osorno, Región DE LOS Lagos
  152. Santiago, Región Metropolitana
  153. Santiago, Región Metropolitana
  154. Santiago, Región Metropolitana
  155. Santiago, Región Metropolitana
  156. Soweto, Gauteng
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
Official Title  ICMJE A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS
Brief Summary

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initial dose.

In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62 subjects.

Detailed Description

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with SIIV. Healthy male and female subjects between 65 to 85 years of age will be enrolled. Subjects will receive 2 intramuscular injections to assess the concomitant administration of SIIV when given to subjects receiving one of the 3 RSV vaccine dose-level candidates formulated with or without an adjuvant.

If interim support implementation of revaccination, invited, consenting subjects will be revaccinated with the same dose and formulation of the RSV vaccine or placebo received at Visit 1, concomitantly with SIIV. The safety, tolerability, and immunogenicity of the second dose will be evaluated through 12 months after revaccination.

62 subjects will be randomized 1:1 to receive a dose of high dose adjuvanted RSV vaccine or placebo followed by a second dose 2 months later. Safety, tolerability, and immunogenicity will be evaluated. The subjects will be enrolled before the influenza season. There will be no concomitant SIIV administration.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Parallel
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Observer blind
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: Formulation A
    RSV vaccine
  • Biological: Formulation B
    Adjuvanted RSV vaccine
  • Biological: Formulation C
    RSV vaccine
  • Biological: Placebo
    Placebo
Study Arms  ICMJE
  • Experimental: Arm 1
    Low dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 2
    Low dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 3
    Mid dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 4
    Mid dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 5
    High dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 6
    High dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 7
    High dose formulation C and SIIV
    Intervention: Biological: Formulation C
  • Placebo Comparator: Arm 8
    Placebo and SIIV
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 10, 2020)
317
Original Estimated Enrollment  ICMJE
 (submitted: June 18, 2018)
474
Actual Study Completion Date  ICMJE August 20, 2020
Actual Primary Completion Date June 23, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
  2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.
  4. Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of enrollment (signing of the ICD).
  5. Subjects must have received the primary vaccination (RSV vaccine or placebo) at Visit 1 and have signed and dated the ICD for participating in the revaccination stage (applies to Primary Study Cohort - Stage 2 subjects).

Exclusion Criteria:

  1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  2. Participation in other studies involving investigational product within 28 days prior to study entry and/or during study participation.
  3. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
  4. Previous vaccination with any licensed or investigational RSV vaccine before enrollment into the study, or planned receipt throughout the study of nonstudy RSV vaccine.
  5. Vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration (applies to Primary Study Cohort - Stages 1 and 2).
  6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product(s), including natural rubber latex. In addition, a history of severe allergic reaction (eg, anaphylaxis) to any substance, including documented allergy to egg proteins (egg or egg products) or chicken proteins.
  7. Subjects with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration.Inhaled/nebulized, intra-articular, intrabursal, or topical (epidural, skin or eyes) corticosteroids are permitted.
  9. Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura, autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  10. Receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration or planned receipt throughout the study.
  11. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  12. Female subjects of childbearing potential or who are pregnant or breastfeeding; fertile male subjects who are unwilling to use a highly effective method of contraception for at least 28 days after the last dose of investigational product.
  13. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  14. Planned donation of blood volumes of approximately 470 mL within 12 weeks after Vaccination 1 (applies to subjects having additional blood drawn for cellular assays).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 65 Years to 85 Years   (Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03572062
Other Study ID Numbers  ICMJE C3671002
RSV ADJUVANT ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP